Read More

Syncona Announced Sunday it Will Acquire Applied Genetic Technologies Corporation for $0.34/Share in Cash Plus Up to $0.73 per CVR

Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases (IRDs), today announced t

AGTC